The litigation alleges that Aardvark Therapeutics leadership disseminated materially misleading information regarding the company's business operations and the safety profile of its lead drug candidate, ARD-101. According to the complaint, the company failed to disclose that the drug was less safe than publicly represented, leading to an overstatement of its clinical and commercial prospects. Investors who believe they were misled by these statements are being urged to contact the firm before the court-mandated deadline to participate in the proceedings. Participation in the class action does not require immediate action from all shareholders, as individuals may choose to retain their own counsel or remain passive members of the class.